SPC
VKTX icon

Sigma Planning Corp’s Viking Therapeutics VKTX Stock Holding History

Sigma Planning Corp’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$516K Sell
13,221
-479
-3% -$15.5K 0.01% 899
2026
Q1 		$446K Buy
13,700
+5,940
+77% +$191K 0.01% 885
2025
Q4 		$273K Buy
+7,760
New +$275K 0.01% 1080
2024
Q4 		– Sell
-15,119
Closed -$957K – 1257
2024
Q3 		$957K Buy
+15,119
New +$887K 0.03% 517

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Sigma Planning Corp's VKTX Position: Q2 2026 in Review

Sigma Planning Corp reduced its Viking Therapeutics (VKTX) stake by 3.5% in Q2 2026, selling an estimated $15.5K and leaving 13,221 shares worth $516K. The position accounts for 0.01% of the portfolio, ranked #899.

Sigma Planning Corp first reported a position in VKTX in Q3 2024 and has held it in 4 quarters since. The position peaked at $957K in Q3 2024. 436 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Sigma Planning Corp held 13,221 shares of Viking Therapeutics worth $516K as of Q2 2026.
  • Sigma Planning Corp sold 479 Viking Therapeutics shares in Q2 2026, an estimated $15.5K.
  • Viking Therapeutics made up 0.01% of Sigma Planning Corp's portfolio in Q2 2026, its #899 holding.
  • Sigma Planning Corp first reported a position in Viking Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • Sigma Planning Corp's Viking Therapeutics position peaked at $957K in Q3 2024.
  • 436 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Sigma Planning Corp's 13F filing for Q2 2026, filed 7 Aug 2026.